Immatics Reports FY25 Revenue of €48.3M
Reports FY25 reports FY25 revenue EUR 48.3M vs. EUR 155.8M last year. "Following a year of strong execution and data updates across our entire PRAME franchise, Immatics is entering 2026 with multiple high-impact milestones ahead, including advancing our PRAME cell therapy, anzu-cel, towards approval," said Harpreet Singh, Ph.D., Chief Executive Officer and Co-Founder of Immatics. "In parallel, we strive to expand our reach to more patients with our second-generation PRAME cell therapy, IMA203CD8, with meaningful data in gynecologic cancers expected this year, and with our PRAME bispecific IMA402, where we plan to report expanded clinical data supporting initiation of indication-specific expansion cohorts. In addition, we look forward to opening a new therapeutic avenue by initiating a combination study with IMA402 and IMA401, our MAGEA4/8 bispecific, in lung cancer. Above all, we remain focused on translating this positive momentum into transformative outcomes for patients with cancer."
Trade with 70% Backtested Accuracy
Analyst Views on IMTX
About IMTX
About the author
Immatics Reports FY Earnings: Revenue and EPS Analysis
- Earnings Overview: Immatics reported a FY GAAP EPS of -€1.61, indicating challenges in profitability that may affect investor confidence and market perception.
- Revenue Performance: The company generated revenue of €48.2M, which, while showing growth, has not reversed the loss situation, highlighting the need for improved product commercialization in a competitive market.
- Market Reaction: Due to ongoing losses and failure to achieve profitability, the market remains cautious about Immatics' future prospects, potentially leading to increased stock price volatility and impacting the company's ability to raise funds.
- Strategic Transition: Immatics is working to transition its PRAME leader into commercial reality; despite financial challenges, successful commercialization could provide long-term growth potential for the company.
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
- Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
- Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
- Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
- Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Immatics Showcases Promising Anti-Tumor Effects of Anzu-cel PRAME Cell Therapy for Metastatic Uveal Melanoma at ESMO 2025 Presidential Symposium
Clinical Trial Results: An ongoing Phase 1b trial of anzu-cel (PRAME cell therapy) in 16 patients with metastatic uveal melanoma shows a confirmed objective response rate of 67%, with a median duration of response of 11 months and median progression-free survival of 8.5 months.
Safety and Tolerability: Anzu-cel demonstrates a favorable tolerability profile, with manageable treatment-emergent adverse events primarily related to cytopenias and cytokine release syndrome, indicating its potential as a treatment option for this difficult-to-treat cancer.
Future Development: Due to the promising results, Immatics has initiated a Phase 2 cohort study for anzu-cel in metastatic uveal melanoma, aiming to expand its application in this area of high unmet medical need.
Company Overview: Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, with a robust pipeline of therapies aimed at various cancers, including ongoing trials for both uveal and cutaneous melanoma.
Immatics Names Venkat Ramanan as Chief Financial Officer
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan as Chief Financial Officer, effective immediately, succeeding Arnd Christ.
Ramanan's Background: Venkat Ramanan brings over 25 years of experience in the biopharmaceutical industry, having previously served as CFO at Anthos Therapeutics, a Novartis company.
Stock Performance: Following the announcement, Immatics' stock closed 7.71% higher at $8.52 on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Immatics Names Venkat Ramanan as CFO
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately, succeeding Arnd Christ. Dr. Ramanan brings over 25 years of experience in the biopharmaceutical industry, having held leadership roles at companies like Seagen, Gilead Sciences, and Amgen.
Focus on PRAME Cell Therapy: Dr. Ramanan's expertise will support Immatics in advancing its PRAME cell therapy, anzu-cel, towards commercialization, particularly for patients with metastatic melanoma, as the company aims to strengthen its position as a leader in precision targeting of PRAME.
Immatics Reports FY Earnings: Revenue and EPS Analysis
- Earnings Overview: Immatics reported a FY GAAP EPS of -€1.61, indicating challenges in profitability that may affect investor confidence and market perception.
- Revenue Performance: The company generated revenue of €48.2M, which, while showing growth, has not reversed the loss situation, highlighting the need for improved product commercialization in a competitive market.
- Market Reaction: Due to ongoing losses and failure to achieve profitability, the market remains cautious about Immatics' future prospects, potentially leading to increased stock price volatility and impacting the company's ability to raise funds.
- Strategic Transition: Immatics is working to transition its PRAME leader into commercial reality; despite financial challenges, successful commercialization could provide long-term growth potential for the company.
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
- Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
- Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
- Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
- Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Immatics Showcases Promising Anti-Tumor Effects of Anzu-cel PRAME Cell Therapy for Metastatic Uveal Melanoma at ESMO 2025 Presidential Symposium
Clinical Trial Results: An ongoing Phase 1b trial of anzu-cel (PRAME cell therapy) in 16 patients with metastatic uveal melanoma shows a confirmed objective response rate of 67%, with a median duration of response of 11 months and median progression-free survival of 8.5 months.
Safety and Tolerability: Anzu-cel demonstrates a favorable tolerability profile, with manageable treatment-emergent adverse events primarily related to cytopenias and cytokine release syndrome, indicating its potential as a treatment option for this difficult-to-treat cancer.
Future Development: Due to the promising results, Immatics has initiated a Phase 2 cohort study for anzu-cel in metastatic uveal melanoma, aiming to expand its application in this area of high unmet medical need.
Company Overview: Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, with a robust pipeline of therapies aimed at various cancers, including ongoing trials for both uveal and cutaneous melanoma.
Immatics Names Venkat Ramanan as Chief Financial Officer
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan as Chief Financial Officer, effective immediately, succeeding Arnd Christ.
Ramanan's Background: Venkat Ramanan brings over 25 years of experience in the biopharmaceutical industry, having previously served as CFO at Anthos Therapeutics, a Novartis company.
Stock Performance: Following the announcement, Immatics' stock closed 7.71% higher at $8.52 on the Nasdaq.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Immatics Names Venkat Ramanan as CFO
New CFO Appointment: Immatics N.V. has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately, succeeding Arnd Christ. Dr. Ramanan brings over 25 years of experience in the biopharmaceutical industry, having held leadership roles at companies like Seagen, Gilead Sciences, and Amgen.
Focus on PRAME Cell Therapy: Dr. Ramanan's expertise will support Immatics in advancing its PRAME cell therapy, anzu-cel, towards commercialization, particularly for patients with metastatic melanoma, as the company aims to strengthen its position as a leader in precision targeting of PRAME.
